Melanotan-1 Injectable vs Oral: Comparison
The choice between injectable and oral Melanotan-1 isn't a trade-off—it's a distinction between a functional delivery method and a non-functional one. Bioavailability 95–100%. Peptide enters circulation intact <0.1%. Complete proteolytic degradation before abs
This comparison does not assign a generated winner or score.
- The choice between injectable and oral Melanotan-1 isn't a trade-off—it's a distinction between a functional delivery method and a non-functional one.
- Bioavailability
- 95–100%. Peptide enters circulation intact
- <0.1%. Complete proteolytic degradation before absorption
- Injectable is the only validated route; oral forms achieve unmeasurable plasma concentrations
- Onset of Action
- 48–72 hours to visible pigmentation increase
- No measurable effect at any dose tested
- Subcutaneous administration is the only method producing MC1R activation
- Half-Life
- 1.5–2.5 hours plasma half-life; melanogenesis persists 7–10 days
- N/A. No systemic exposure
- Injectable formulations maintain therapeutic effect for one week per dose
- Enzymatic Stability
- Bypasses GI proteases entirely; reaches receptors intact
- Degraded by pepsin, trypsin, chymotrypsin within 20–30 minutes
- Digestive enzymes render oral peptides biologically inert
- FDA-Approved Formulation
- Scenesse (afamelanotide implant, 16mg controlled-release)
- None. No oral Melanotan-1 product has FDA approval
- Regulatory approval only exists for injectable/implant routes
- Cost per Dose
- Research-grade vials $40–$80 per 10mg (5–10 doses depending on protocol)
- Variable, but irrelevant—oral forms produce no effect
- Price comparison is moot when oral administration fails pharmacokinetically
- This table underscores a fundamental principle: peptide structure dictates delivery method. Melanotan-1's amino acid sequence cannot be altered without destroying MC1R binding affinity, and that sequence cannot survive oral administration without carrier technology that doesn't yet exist for this compound.